Key Points
- CEO Helen Torley sold 10,000 shares on Feb. 5 at an average price of $78.64 for $786,400, and has made several recent sales (20,000 on Feb. 3; 16,569 on Dec. 1; 20,000 on Nov. 11), leaving her with 708,719 shares — a 1.39% ownership decline.
- Strong recent results: Halozyme reported Q results with $1.72 EPS (beat $1.63) and $354.3M revenue (up 22.1% y/y and above estimates), and the stock sits near its 1-year high with a $9.39B market cap.
- Mixed analyst view and high institutional ownership: The stock's average analyst rating is "Hold" with a $78.80 target, while institutional investors own 97.79% of shares outstanding.
Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) CEO Helen Torley sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Thursday, February 5th. The stock was sold at an average price of $78.64, for a total transaction of $786,400.00. Following the sale, the chief executive officer directly owned 708,719 shares of the company's stock, valued at $55,733,662.16. This represents a 1.39% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Helen Torley also recently made the following trade(s):
- On Tuesday, February 3rd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $76.12, for a total value of $1,522,400.00.
- On Monday, December 1st, Helen Torley sold 16,569 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $68.92, for a total value of $1,141,935.48.
- On Tuesday, November 11th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $69.13, for a total value of $1,382,600.00.
Halozyme Therapeutics Stock Performance
NASDAQ:HALO opened at $79.85 on Friday. The company has a market capitalization of $9.39 billion, a price-to-earnings ratio of 16.73, a PEG ratio of 0.32 and a beta of 0.97. The business has a 50 day moving average of $69.23 and a 200 day moving average of $68.91. The company has a debt-to-equity ratio of 1.59, a current ratio of 1.59 and a quick ratio of 1.37. Halozyme Therapeutics, Inc. has a 1-year low of $47.50 and a 1-year high of $79.50.
Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 EPS for the quarter, topping the consensus estimate of $1.63 by $0.09. The firm had revenue of $354.26 million for the quarter, compared to the consensus estimate of $339.18 million. Halozyme Therapeutics had a net margin of 47.91% and a return on equity of 156.95%. The business's revenue was up 22.1% compared to the same quarter last year. During the same period last year, the firm posted $1.27 earnings per share. On average, sell-side analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Halozyme Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of HALO. Moran Wealth Management LLC grew its position in shares of Halozyme Therapeutics by 0.4% in the 4th quarter. Moran Wealth Management LLC now owns 35,596 shares of the biopharmaceutical company's stock worth $2,396,000 after buying an additional 151 shares during the last quarter. Campbell Newman Asset Management Inc. boosted its holdings in Halozyme Therapeutics by 0.4% in the third quarter. Campbell Newman Asset Management Inc. now owns 36,878 shares of the biopharmaceutical company's stock valued at $2,705,000 after acquiring an additional 153 shares in the last quarter. Coldstream Capital Management Inc. increased its position in Halozyme Therapeutics by 1.9% during the 3rd quarter. Coldstream Capital Management Inc. now owns 8,914 shares of the biopharmaceutical company's stock valued at $654,000 after purchasing an additional 165 shares during the period. Alps Advisors Inc. raised its holdings in Halozyme Therapeutics by 3.0% in the 3rd quarter. Alps Advisors Inc. now owns 5,926 shares of the biopharmaceutical company's stock worth $435,000 after purchasing an additional 170 shares in the last quarter. Finally, EverSource Wealth Advisors LLC raised its holdings in Halozyme Therapeutics by 6.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company's stock worth $140,000 after purchasing an additional 174 shares in the last quarter. Hedge funds and other institutional investors own 97.79% of the company's stock.
Analyst Upgrades and Downgrades
Several research firms have weighed in on HALO. Weiss Ratings downgraded shares of Halozyme Therapeutics from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Monday, January 26th. JPMorgan Chase & Co. boosted their target price on Halozyme Therapeutics from $63.00 to $65.00 and gave the company a "neutral" rating in a research note on Monday, October 27th. The Goldman Sachs Group restated a "sell" rating and set a $56.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, December 4th. Benchmark reaffirmed a "buy" rating on shares of Halozyme Therapeutics in a research note on Tuesday. Finally, TD Cowen increased their price objective on Halozyme Therapeutics from $79.00 to $90.00 and gave the company a "buy" rating in a research note on Thursday, January 8th. Seven research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $78.80.
Get Our Latest Research Report on Halozyme Therapeutics
About Halozyme Therapeutics
(
Get Free Report)
Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.
The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
